Opyl Limited to introduce Opin www.opin.ai: a patient-led platform giving people the ability to self-select an interest in any clinical trial or research study anywhere in the world. For the first time patients and carers will have the ability to see and self-select to any clinical trial and research study registered to any regulatory authority, that is open and recruiting participants, on a global scale in one website. Opin is the first major platform the company has commercialised as a scalable enterprise model. The platform is free-of-charge for patients to use and will generate revenue in three ways: by charging research organizations conducting trials a fee to unlock matched patient data, charging to have trials featured on the platform and in social media channels, and using the platform sophisticated data search capability to find matched patients registered to the platform waiting for a trial or study opportunity to open up, anywhere in the world. When patients become genuine partners in their healthcare, and have the opportunity and motivation to learn more and actively participate in decision-making, they generally can achieve much better health outcomes. More than 80% of clinical trials fail to recruit on time and on budget 1. Each month of delay caused by recruitment can cost a biopharmaceutical, medtech or research institute tens or even hundreds of millions of dollars. The cost of clinical trial recruitment represents between 25-33% of clinical trial budget, therefore addressing recruitment inefficiencies, as Opin can do, represents one of the most significant ways to reduce financial wastage in the research sector. A key feature of the Opin approach, and one of their competitive advantages, is in leveraging social media and digital channels to create awareness and a door through which patients and carers can open to access the platform. The Opyl team have been experts in using social media and digital marketing strategies to attract and support patient recruitment to studies and trials for over four years. Opin represents the conversion of years of consulting experience into a scalable, global enterprise solution. The Opin platform incorporates some of the novel AI and predictive analytics technology that Opyl has been developing in the background aimed at improving protocol (clinical trial plan) design.